Skip to main content

Advertisement

Table 3 Gametocyte prevalence on days 0, 7, 14, 21 and 28 after treatment in patients with adequate parasitological response

From: Randomized clinical trial of artemisinin versus non-artemisinin combination therapy for uncomplicated falciparum malaria in Madagascar

  Gametocyte prevalence, %, (n/N)
   After treatment
  At enrolment Day 7 Day 14 Day 21 Day 28
CQ 4.7 (2/42) 12.5 (3/24)* 4.2 (1/24)* 6.6 (1/15) 0 (0/15)
AQ 12.8 (5/39) 13.1 (5/38)* 10.5 (4/38)* 9.6 (3/31) 0 (0/30)
SP 10.2 (4/39) 44.4 (16/36) 33.3 (12/36) 17.1 (6/35) 6.1 (2/33)
AQ+SP 2.4 (2/83) 3.8 (3/80)* 6.3 (5/80)* 1.3 (1/75) 1.3 (1/75)
AQ+AS 3.6 (3/83) 2.5 (2/80)* 1.2 (1/79)* 1.5 (1/64) 0 (0/64)
  1. CQ, Chloroquine, AQ, amodiaquine; SP, Sulphadoxine-Pyrimethamine; AS, artesunate; 95% CI, 95% confidence interval.
  2. * On day 7 and day 14, significant difference to SP group (P < 0.05)
  3. ¶On day 21, significant difference to SP group (P < 0.05)